 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
Clinical, Journal: Immunogenicity and safety of live attenuated influenza vaccine in children aged 3-17 (Pubmed Central) - Dec 28, 2024
(3) Although there was no significant difference in frequencies of all solicited or unsolicited AEs, nasal congestion, headache, and muscle pain were statistically significantly more frequent in vaccine recipients as compared to placebo Seroconversions and geometric mean fold increases in HI antibody titers against all strains were significantly higher in the vaccine group than in the placebo group. (4) The LAIV is safe and immunogenic in Chinese children and adolescents.
- ||||| live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
New P4 trial: Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine (clinicaltrials.gov) - Feb 28, 2024
P4, N=6080, Recruiting, Sponsor: Changchun BCHT Biotechnology Co.
- || live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
Clinical, Journal: Safety and Viral Shedding of Live Attenuated Influenza Vaccine (LAIV) in Chinese Healthy Juveniles and Adults: A Phase Ⅰ Randomized, Double-Blind, Placebo-Controlled Study. (Pubmed Central) - Nov 15, 2022
Pathogenicity of shed vaccine virus to surrounding people was not observed. Thus, Phase Ⅱ study can be carried out as scheduled.
- ||||| live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
New P2 trial: The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine (clinicaltrials.gov) - Mar 16, 2022
P2, N=2520, Not yet recruiting, Sponsor: Changchun BCHT Biotechnology Co.
- ||| live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
New P1 trial: The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine (clinicaltrials.gov) - Sep 23, 2021
P1, N=160, Recruiting, Sponsor: Changchun BCHT Biotechnology Co.
- ||| live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
New trial: To Explore a Bridging Index for the Effectiveness of the Clinical Trial (clinicaltrials.gov) - Apr 1, 2021
P=N/A, N=450, Not yet recruiting, Sponsor: Changchun BCHT Biotechnology Co.
- ||||||| live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
Trial completion, Trial primary completion date: A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV) (clinicaltrials.gov) - Sep 14, 2017
P3, N=9000, Completed, Sponsor: Changchun BCHT Biotechnology Co.
Thus, Phase Ⅱ study can be carried out as scheduled. Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Aug 2017
- ||||| live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
Enrollment closed: A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV) (clinicaltrials.gov) - Jan 24, 2017
P3, N=9000, Active, not recruiting, Sponsor: Changchun BCHT Biotechnology Co.
Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Aug 2017 Recruiting --> Active, not recruiting
- || live influenza vaccine (freeze-dried) / Changchun BCHT Biotechnology
New P3 trial: A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV) (clinicaltrials.gov) - Nov 14, 2016
P3, N=9000, Recruiting, Sponsor: Changchun BCHT Biotechnology Co.